JAK1 and chronic neutrophilic leukemia: The discovery of the key role of CSF3R in CNL and the JAK/STAT signaling pathway in CNL pathobiology has impelled the investigation of ruxolitinib, a JAK1/2 inhibitor, for the treatment of CNL.